Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 5 Jan 2017 |
| Genmab to Present at the 35th Annual J.P. Morgan Healthcare Conference | 4 Jan 2017 |
| Articles of Association for Genmab A/S | 21 Dec 2016 |
| Genmab Announces Submission of Regulatory Application for Daratumumab in Relapsed/Refractory Multiple Myeloma in Japan and Updates Financial Guidance | 20 Dec 2016 |
| Grant of Restricted Stock Units to Board Members, Management and Employees and Grant of Warrants to Management and Employees in Genmab | 15 Dec 2016 |